To quantitatively evaluate the role of Epstein-Barr virus (EBV)-encoded latent membrane protein 2A (LMP2A) in immortalization of peripheral Blymphocytes, we used the Akata cell system to generate an EBV recombinant in which the first exon of the LMP2A gene was disrupted. The results indicated that deletion of the LMP2A gene did not affect the immortalization efficiency of EBV in Blymphocytes. Deletion of the LMP2A gene made EBV-transformed lymphocytes more permissive for virus replication in response to surface immunoglobulin cross-linking. On the other hand Akata cells, in which LMP2A expression was much lower than in EBV-transformed lymphocytes, were equally permissive for virus replication whether they were infected with wild EBV or LMP2A-knockout EBV. The results raise a question as to the role of LMP2A in inhibition of disruption of virus latency in vivo, where LMP2A expression has been expected to be low as in Akata cells.
Epstein-Barr virus (EBV), a human herpesvirus, is the causative agent of infectious mononucleosis, and is associated with various malignancies such as Burkitt's lymphoma and nasopharyngeal carcinoma (Rickinson & Kieff, 1996) . EBV is ubiquitous in humans, establishes latent infection in peripheral B-lymphocytes following primary infection, and persists for the remainder of the host's lifetime. In vitro, EBV transforms peripheral B-lymphocytes into indefinitely growing lymphoblastoid cells (LCL) . LCL maintain the entire viral genome mostly in a plasmid form and express a limited number of virus gene products, including six nuclear antigens (EBNA1, EBNA2, EBNA3A, EBNA3B, EBNA3C and EBNALP), three latent membrane proteins (LMP1, LMP2A and LMP2B), two small nonpolyadenylated RNAs (EBER1 and EBER2) and the transcripts from the BamHI-A region (BARF0) (Kieff, 1996) .
Author for correspondence : Kenzo Takada.
Fax j81 11 717 1128. e-mail kentaka!med.hokudai.ac.jp LMP2A and LMP2B are transcribed from unique and common exons (Laux et al., 1988 ; Sample et al., 1989) . The first exon is unique to LMP2A and encodes a 119 amino acid cytoplasmic amino-terminal domain. The remaining eight exons are common with LMP2B, and encode 12 hydrophobic membrane-spanning domains and a 27 amino acid cytoplasmic carboxy-terminal domain. The amino-terminal part of LMP2A is associated with src family protein tyrosine kinases (Burkhardt et al., 1992 ; Longnecker et al., 1991) . LMP2A is a substrate for these protein kinases, acts as a dominant negative regulator of lyn and fyn protein kinase activities, and interferes with signal transduction after cross-linking of cell surface immunoglobulin (sIg) (Miller et al., a, 1995 . Cross-linking of sIg efficiently activates a switch to lytic EBV gene expression in latently EBV-infected cells (Takada, 1984 ; Takada & Ono, 1989) . LMP2A prevents lytic reactivation in response to sIg cross-linking in EBV-immortalized B-lymphocytes (Miller et al., 1994 b) , and is thought to maintain a latent state of EBV infection in vivo, because only EBNA1 and LMP2A were reported to be expressed in latently EBV-infected B-cells in vivo (Chen et al., 1995 ; Miyashita et al., 1997 ; Qu & Rowe, 1992 ; Tierney et al., 1994) .
Concerning the role of LMP2A in B-cell immortalization, there have been reports from two groups. R. Longnecker and colleagues reported that LMP2A was dispensable for B-cell immortalization. Two EBV mutants were generated : one a knockout of the first exon of the LMP2A gene Speck et al., 1999) , and the other of the last seven transmembrane and carboxy-terminal cytoplasmic domains , which are shared with LMP2B, and therefore the latter mutant is deficient in both LMP2A and LMP2B genes. An EBV recombinant was generated in EBVproducing P3HR-1 cells and B95-8 cells as a mixture of wild EBV and mutant EBV, which was then used to immortalize primary B-lymphocytes. LMP2A-or LMP2A\2B-knockout EBV released from immortalized B-cells was demonstrated to have an ability to immortalize primary B-lymphocytes. However, the assays were not quantitative because the virus preparations always contained both wild and mutant EBV. On the other hand, W. Hammerschmidt and colleagues (Brielmeier et al., 1996) reported that LMP2 was important for efficient B- . When the plasmid recombines into the targeting site, novel 8n3 kb EcoRI-BamHI and 11n3 kb EcoRI-SacII fragments will appear. Probes used for Southern blot analysis are indicated at the bottom. B, BamHI ; E, EcoRI ; Bg, BglII ; M, MunI; S, SacII ; TR, terminal repeat. (B, C) Southern blot analysis of a targeted Akata cell clone and LMP2A-knockout EBV-infected Akata − clones. Two µg of cellular DNA was doubly digested with EcoRI/BamHI (B) or EcoRI/SacII (C), blotted, and hybridized with the EcoRI/BamHI or neo r probe (B) or SacII or neo r probe (C) by the procedure described previously (Shimizu et al., 1994 ) (see Fig. 1 A) . (D) LMP2A expression in LMP2A-knockout EBV-infected Akata cell clones by RT-PCR analysis. Total cellular RNA was isolated by guanidium isothiocyanate-phenol extraction using TRIzol reagent (GibcoBRL) according to the manufacturer's protocol. One µg of total RNA was treated with DNase I (GibcoBRL) and incubated with Moloney murine leukaemia virus reverse transcriptase (GibcoBRL). The cDNA (corresponding to 100 ng of total RNA) was subjected to PCR using primers 5' CCCTAGAAATGGTGCCAATG 3' and 5' CATGTTAGGCAAATTGCAAA 3'. One-tenth of the PCR product was electrophoresed in a 2 % agarose gel, blotted, and hybridized with a 32 P-labelled oligonucleotide probe (5' ATCCAGTATGCCTGCCTGTA 3'). LCL immortalized by Akata EBV were used as a positive control. The EBV-negative B-lymphoma line BJAB was used as a negative control. (E) LMP2A expression in LMP2A-knockout EBV-immortalized LCL by immunoblot analysis. Protein samples (corresponding to 4i10 5 cells) were separated in 10 % polyacrylamide gels and transferred to nitrocellulose membranes (Schleicher and Schuell). LMP2A was detected with a rabbit polyclonal antibody. LCL immortalized by LMP2A-positive Akata EBV were used as a positive control. BJAB cells were used as a negative control.
cell immortalization. Knockout EBV was generated in an E. coli F-factor-based plasmid and packaged in P3HR-1 cells, which were infected with EBNA2-deleted, transformation-incompetent EBV. This assay, however, could not evaluate the function of LMP2A, because the knocked-out LMP2 regions were common to both LMP2A and LMP2B.
Our present study aimed to quantitatively determine the role of LMP2A in B-cell immortalization by using a pure recombinant EBV preparation generated by an Akata cell system (Shimizu et al., 1996) . We also studied whether the small amount of LMP2A expressed in Akata cells, which must be similar to that in latently EBV-infected B cells in vivo, had any effect on preventing activation of latent EBV.
The Akata cell line, derived from Burkitt's lymphoma, was originally 100 % EBV-positive (Takada et al., 1991) . We isolated EBV-positive and -negative subclones from the parental Akata 
cell culture by the limiting dilution method. EBV-positive Akata cells (Akata + cells) have " 20 copies of EBV plasmid per cell. The first exon of the LMP2A gene of an EBV plasmid was disrupted by insertion of the neomycin resistance gene (neo r ) by homologous recombination (Fig. 1 A) . The targeting plasmid was the BglII fragment encompassing the first exon of LMP2A (Sample et al., 1989) , disrupted by insertion of neo r . The plasmid was transfected into Akata + cells by the electroporation method. Transfected Akata cells were cultured in 96-well, flat-bottom plates at 5000 cells per well in complete culture medium containing 700 µg\ml of G418 (Life Technologies). A total of 984 G418-resistant Akata cell clones appeared from 2880 wells tested. Southern blot analysis indicated that two clones contained homologously recombined EBV. Fig.  1 (B, C) shows a clone that contained an EBV recombinant with the neo r DNA recombined into the expected LMP2A site, as well as non-recombinant (wild) Akata EBV. On the EcoRI\ BamHI double-digested blot (Fig. 1 B) , the 6n8 kb EcoRI-BamHI subfragment of the EBV BamHI-A fragment was used as a probe and identified a 6n8 kb wild EBV band as well as an 8n3 kb recombinant EBV band, which hybridized to the neo r probe also (see Fig. 1 A) . On the EcoRI\SacII double-digested blot (Fig. 1 C) , the 3n7 kb SacII subfragment of the EBV BamHINhet fragment was used as a probe and identified a 3n7 kb wild EBV band as well as an 11n8 kb recombinant EBV band that hybridized to the neo r probe also (see Fig. 1 A) .
Then, EBV-negative Akata cells (Akata − , 5i10') (Shimizu et al., 1994) were infected with the virus preparation from G418-resistant Akata cells, which contained a mixture of wildtype EBV and recombined EBV. Two days after infection, cells were plated in 96-well, flat-bottom plates at 5000 cells per well with complete medium containing 700 µg G418\ml. Twelve G418-resistant clones were examined and proved to be infected with recombinant EBV only. Southern blot analysis indicated that the recombinant EBV-infected Akata − cells had the neo r DNA exactly recombined into the first exon of the LMP2A gene (Fig. 1 B, C) . RT-PCR analysis indicated that LMP2A-knockout EBV-infected Akata cells were negative for LMP2A mRNA expression (Fig. 1 D) . Furthermore, immunoblot analysis indicated that LCLs immortalized by LMP2A-knockout EBV were negative for LMP2A expression (Fig. 1 E) .
At first, we compared virus production by Akata cells harbouring the LMP2A-knockout EBV with that of Akata cells harbouring recombinant EBV with insertion of the neo r gene at the BXLF1 gene (referred to as wild EBV), which is known to be non-essential for EBV infection and replication. In three cell clones, LMP2A-knockout EBV-infected Akata cells produced 4n2, 4n5 and 5n3 µg of viral DNA per litre of culture supernatant, and wild EBV-infected Akata cells produced 2n9, 4n0 and 5n8 µg of viral DNA per litre of culture. Equal amounts of virus (corresponding to 4 ng of viral DNA) from both wild-type EBV and LMP2A-knockout EBV preparations were diluted 10-fold, inoculated to cord blood mononuclear cells (10' cells), and their ability to immortalize primary B-lymphocytes was assessed. In two separate experiments, the 50 % immortalization doses per 4 ng of viral DNA were 10% n ) and 10& n # for LMP2A-knockout EBV, and 10& n # and 10% n ' for wild EBV. These results indicated that there was no difference in immortalization efficiency between wild EBV and LMP2A-knockout EBV.
Akata cells express a small amount of LMP2A that is . Cell clones that stably expressed LMP2A protein were selected and analysed. Protein samples (corresponding to 4i10 5 cells) were separated in 10 % polyacrylamide gels and transferred to a nitrocellulose membrane (Schleicher and Schuell). LMP2A was detected with a rabbit polyclonal antibody. LCL immortalized by LMP2A-positive Akata EBV were used as a positive control. BJAB cells were used as a negative control.
detectable by RT-PCR but not by immunoblot analysis. We examined whether this amount of LMP2A expression had any effect on sIg-mediated calcium mobilization. Wild EBVinfected and LMP2A-knockout EBV-infected Akata cells were treated with anti-Ig, and their intracellular free calcium levels were measured by flow cytometry (Table 1) . Both wild EBVinfected and LMP2A-knockout EBV-infected Akata cells exhibited similar changes in intracellular calcium.
As compared with LMP2A expression in Akata cells, LCL expresses a higher level of LMP2A, and it has been reported that LMP2A in LCL blocks sIg-mediated signalling . The responses to anti-Ig treatment of LCLs immortalized with wild EBV and LMP2A-knockout EBV were compared. (Table 1) . LCLs immortalized by LMP2A-knockout EBV displayed increased calcium mobilization in response to anti-Ig compared with LCL immortalized by wild EBV. Both the percentage of cells responding and the percentage change in the intracellular calcium level increased in LCL transformed by LMP2A-knockout EBV compared with wild EBV.
Next we examined whether high-level expression of LMP2A comparable to the level in LCL could inhibit calcium mobilization induced by anti-Ig treatment. The LMP2A expression plasmid was generated from cDNA of Akata EBVimmortalized LCL by a PCR-based strategy. Total cellular RNA was reverse-transcribed using the 3'LMP2A primer (GCACATTGGGTTTATTGTAGTGTTTGTAAATAC). The cDNA was then subjected to 35 cycles of PCR using primers 3'LMP2A and 5'LMP2A (TTAGCGCTGCTGCAG-CTATGGGGTCCCTAG). The amplified DNA was sequenced to confirm the absence of any mutations introduced by PCR. Compared with the nucleotide sequence of the B95-8 strain (Baer et al., 1984) , there were three base changes, which resulted in three amino acid changes (tyrosine-23 to aspartate, and serine-348 and -444 to isoleucine). Tyrosine-23 has been reported to be dispensable for blocking B-cell signal transduction (Fruehling et al., 1996) . The cDNA of LMP2A was further cloned into the pSG5 vector containing neo r and transfected into BJAB, Akata − and Akata + cells. Cell clones that had LMP2A levels similar to those of LCL were isolated (Fig. 2 A, B, C) and examined for their calcium mobilization response to anti-Ig treatment. In all three cell lines, LMP2A-transfected cell clones showed reduced numbers of cells responding, as well as a reduction in the degree to which responding cells mobilized calcium, compared with those of vector-transfected clones (Table 1) .
It is well known that Ig receptor signalling induces activation of latently infected EBV (Takada, 1984) . Therefore, we compared the levels of lytic antigen expression after anti-Ig treatment between wild EBV-infected and LMP2A-knockout EBV-infected Akata cells. The results are shown in Table 1 . There was no difference in the frequency of lytic antigen-positive cells. These results suggest that a small amount of LMP2A in type I latency does not block sIgmediated signalling.
We then compared the level of lytic antigen expression after anti-Ig treatment between wild EBV-infected and LMP2A-knockout EBV-infected LCL. The results indicated that wild EBV-infected LCLs showed very little or no induction of EBV lytic antigens, while LMP2A-knockout EBV-infected LCLs produced EBV early antigens (EA) and viral capsid antigens (VCA) in 5 % and 1 % of cells, respectively, after antiIg treatment.
Next Akata + cells, which expressed a small amount of LMP2A, were transfected with the LMP2A plasmid, and cell clones that constitutively expressed LMP2A at a level similar to LCL were isolated. These cell clones became less permissive for virus replication as compared with Akata + cell clones transfected with the neo r plasmid as a control.
Our results showed clearly that deletion of the LMP2A gene did not affect the immortalization efficiency of EBV in peripheral lymphocytes. Brielmeier et al. (1996) reported that the deletion of both LMP2A and LMP2B genes from EBV lowered the lymphocyte immortalization efficiency remarkably. It remains to be studied whether LMP2B plays some role in lymphocyte immortalization.
LCL express a high level of LMP2A protein, which can be detected by Western blot. The high-level expression of LMP2A in LCL is caused by transactivation of the EBNA2 protein (Zimber et al., 1993) . On the other hand, Akata cells are negative for EBNA2 expression and express little LMP2A. The analysis of peripheral blood lymphocytes by PCR showed that only EBNA1 and LMP2A were expressed in EBV latency in vivo (Chen et al., 1995 ; Miyashita et al., 1997 ; Qu & Rowe, 1992 ; Tierney et al., 1994) . Although the level of LMP2A expression in peripheral lymphocytes has not been measured quantitatively, the absence of EBNA2 expression suggests a low level of LMP2A expression in these cells. Our results showed that the low level of LMP2A expressed in Akata cells could not block the EBV activation by cross-linking of sIg, suggesting that a low level of LMP2A expression in in vivo latency could not block EBV activation.
